Debbie Rigby takes a look at the latest in research news
A Scottish cohort study has use of proton pump inhibitors (PPIs) and H2 receptor antagonists (H2RA) is associated with increased rates of C. difficile and Campylobacter positive gastroenteritis in both the community and hospital settings.
Br J Clin Pharmacol, doi: 10.1111/bcp.13205.
A systematic review and meta-analysis of 138 studies on screening tests for pre-diabetes and efficacy of interventions (lifestyle or metformin) in preventing onset of type 2 diabetes in people with pre-diabetes has concluded that HbA1c is neither sensitive nor specific for detecting pre-diabetes; and fasting glucose is specific but not sensitive. The editorial agrees that preventing or delaying type 2 diabetes requires other effective measures to motivate the general population to protect their own health.
A meta-analysis of 26 studies examined the cardiovascular risk of NSAIDs, comparing drugs, against placebo, and against non-selective NSAIDs (nsNSAIDs). Drugs were also compared against COX-2 selective inhibitors (COXIBs) with and without inclusion of rofecoxib. No NSAID reached statistical significance in regard to CV death. Rofecoxib was the only drug to demonstrate harm and skewed the data of the COX-2 selective group.
Journal of Clinical Pharmacy and Therapeutics 2017;42:27–38.
Analysis of data from 278 205 Swedish people shows long-term use of PPI occurs in one out of nine (12%) individuals in the older population. For four out of ten (38%) of these, no reason for PPI use can be identified. Nursing home residence, female sex, and greater number of drugs predict non-rational long-term use of PPI.
Pharmacoepidemiology and drug safety (2016)